Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Association Between Inflammatory Bowel Disease and Viral Infections

“…In other investigations, researchers found that patients with IBD treated with the anti-TNF drug infliximab, which was linked to an increased risk of SARS-CoV-2 infection, had vaccine-induced antibody responses that were less robust and lasting than patients treated with the anti-integrin drug vedolizumab, which has a gut-specific mode of action and does not result in systemic immunosuppression. These findings, and data from other immunosuppressed patient populations, have given evidence supporting the prioritization of third primary SARS-CoV-2 vaccine doses for patients with IBD who receive immunosuppressive therapy [36,37].…”

COVID-19 und chronisch-entzündliche Darmerkrankungen

“…Patient*innen mit TNF-Antikörper-Therapien sollten deshalb auf die Möglichkeit und Notwendigkeit der 2. Booster-Impfung hingewiesen werden [ 34 ].…”

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD

“…In The Lancet Gastroenterology & Hepatology , Zhigang Liu and colleagues, 1 on behalf of the CLARITY-IBD study investigators, report on the effect of different immunomodulating treatments commonly prescribed to patients with inflammatory bowel disease (IBD) on serological responses against the highly transmissible SARS-CoV-2 omicron (B.1.1.529) variants (BA.1 and BA.4 and BA.5 [hereafter BA.4/5]). In this prospective, multicentre, cohort study, functional neutralising antibody responses against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants after three doses of SARS-CoV-2 vaccine were investigated in 1288 patients with IBD without previous SARS-CoV-2 infection, and who were treated with either infliximab (n=871) or vedolizumab (n=417) recruited from infusion units across the UK.…”

“…Continued assessment of the effect of immunomodulating treatment on the antiviral immune response is essential, especially when considering the ongoing spread of novel dominant SARS-CoV-2 variants caused by viral mutation drift driving global infection rates. The study of Liu and colleagues 1 highlights the consequences of infliximab and vedolizumab therapy for neutralising antibody responses against omicron BA.1 and BA.4/5 variants for patients with IBD; however, similar efforts for other immunosuppressive agents like methotrexate and JAK inhibitors are also important, because these treatments are likely to affect vaccine-induced immunity against SARS-CoV-2. 3 More real-world evidence is required to inform vaccine prioritisation in the foreseeable future.…”

“…An important point of discussion relates to focusing on specific immunological domains when assessing the immune response after vaccination. Liu and colleagues 1 focused on the humoral immune response through examination of functional neutralising antibody responses. Although this functional neutralising capacity reflects efficient protection against SARS-CoV-2 infection, it only partially informs on immunological protection.…”